Treatment of bleeding with low half-life fibrinogen
AssigneeLaboratoire Francais Du Fractionnement Et Des Biotechnologies
InventorsFrank Pieper, Anurag Relan, Erik Jordahl Forsberg
Life of this patent
Estimating the term…
Abstract
The invention provides low-half life fibrinogen with reduced sialyation as a result of recombinant expression or enzymatic and chemical removal. The low-half life fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable.
Claims14
A method of treating or effecting prophylaxis in a patient who is bleeding or is at risk of bleeding, comprising administering a dose of recombinant fibrinogen having a reduced half-life relative to natural human plasma fibrinogen to the patient, wherein the peak plasma concentration of recombinant fibrinogen is greater than 1 g/L.
A method of treating or effecting prophylaxis in a patient who is bleeding or at risk of bleeding, comprising administering fibrinogen having a reduced half-life relative to natural human plasma fibrinogen to the patient, wherein the treatment is in a regime sufficient to achieve a peak concentration of fibrinogen in plasma including administered and endogenous fibrinogen that is within or above normal levels, and wherein the plasma concentration declines to normal or below normal levels within three days of first administration.
Dependencies are inferred from the claim text.